EPO and sarcopenia: Study 7 (Table 1) [24] assessed the effects of recombinant human erythropoietin (EPO), already used in in sarcopenic patients for perioperative recovery, in patients with femoral intertrochanteric fracture and sarcopenia, to investigate its potential benefits on postoperative rehabilitation.